Download by
Scanning QR Code
No Stock Yet
No Data
Pharmaceutical and Biological Industry Research and medium-term Strategy: grasping the New dividend under the upgrading of Pharmaceutical Industry
Tengsheng Bo Pharmaceutical-B (02137) granted 2.376 million share options and 981000 restricted shares
Zhitong Financial App News, Tengsheng Boyao-B (02137) announced that on June 24, 2022, the company granted 2.376 million share options to 20 share option transferees under the terms of the post-IPO share option plan, at an exercise price of HK $9.16 per share, subject to the acceptance of the share option transferee. As at the date of this announcement, the total number of shares in issue is 723 million. Upon full exercise of these options, the shares to be allotted and issued accordingly account for about 0.33% of the total number of shares issued at the date of this announcement and about 0.33% of the total number of enlarged issued shares of the company (no
Changes in Hong Kong stocks | via Bio (01873) rose more than 12%, leading biomedical stocks to be optimistic about the increase in the attention of Chinese biomedical companies.
Zhitong Financial APP learned that biomedical stocks were among the biggest gainers today, with via Bio (01873) up 12.4% to HK $2.81, Kang Fang Bio-B (09926) up 11.84% to HK $21.45, Tengsheng Bo Medicine-B (02137) up 8.92% to HK $8.91, and Rongchang Bio (09995) up 7.86% to HK $37.75. China Merchants reported that at this year's ASCO meeting, a total of 11 abstracts related to innovative drugs by Chinese biomedical companies were selected into the oral report section of the conference (5 of which were PD-).
[HK] Tengshengbo Pharmaceuticals-B (02137): latest information on voluntary announcement business
SVB Securities raises the target price of 2137.HK to HK $19 per share
SVB Securities has been raised recently
Changes in Hong Kong stocks | Tengsheng Boyao-B (02137) the production of ambavirin and romisovir injection basically meets the requirements of drug production quality management standards.
Zhitong Financial APP learned that Tengsheng Bo Pharmaceutical-B (02137) announced that its holding company Tengsheng Huachuang Pharmaceutical Technology (Beijing) Co., Ltd. (hereinafter referred to as "Tengsheng Huachuang") in the Beijing Municipal Drug Administration of Tengsheng Huachuang and its entrusted producers, Wuxi Yaoming Biotechnology Co., Ltd. And Shanghai Yaoming Biotechnology Co., Ltd. The formal inspection conclusion was obtained after the production quality management specification (GMP) conformance test was carried out for the original solution and preparation workshop of new crown neutralizing antibody ambavirin injection and romisovir monoclonal antibody injection. As of 09:20, it was up 6.65% at
Tengshengbo drug-B (02137.HK): the production of ambavirin and romisovir injection is basically in line with the Drug production quality Management Standard (revised in 2010) and its appendix requirements.
02137.HK announced that its holding company, Tengsheng Huachuang Pharmaceutical Technology (Beijing) Co., Ltd. (hereinafter referred to as "Tengsheng Huachuang"), announced in the Beijing Municipal Drug Administration on Tengsheng Huachuang and its entrusted producers, Wuxi Yaoming Biotechnology Co., Ltd and Shanghai Yaoming Biotechnology Co., Ltd. The formal inspection conclusion was obtained after the production quality management standard ("GMP") conformance test was carried out for the original solution and preparation workshop of new crown neutralization antibody ambavirin injection and romisciumab injection. It is concluded that the injection of ambavirin monoclonal antibody
Tengshengbo drug-B (02137): the production of ambavirin injection and romisovir injection basically meets the requirements of drug production quality management standards.
Zhitong Financial App News, Tengsheng Bo Pharmaceutical-B (02137) announced that its holding company Tengsheng Huachuang Pharmaceutical Technology (Beijing) Co., Ltd. (hereinafter referred to as "Tengsheng Huachuang") in the Beijing Municipal Drug Administration of Tengsheng Huachuang and its entrusted producers, Wuxi Yaoming Biotechnology Co., Ltd. And Shanghai Yaoming Biotechnology Co., Ltd. The formal inspection conclusion was obtained after the production quality management specification (GMP) conformance test was carried out for the original solution and preparation workshop of new crown neutralizing antibody ambavirin injection and romisovir monoclonal antibody injection.
Celebration of the fourth Anniversary of Tengsheng Boyao: spring and autumn, ready to go
About Tengshengbo medicine
The General Office of the State Council issued the key tasks of deepening the Reform of the Medical and Health system in 2022
Loading...
No Stock Yet